文献速递乳腺癌

美国女性致病性变异、家族史与乳腺癌累积风险

Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women.
PubMed 文献 · JAMA Oncol · 2025-01-01

结果显示,PALB2 PV携带者有家族史者50岁累积风险达35.5%,而无PV无家族史者仅2.4%;风险因家族史和可改变流行病学因素而异。

要点

  • ATM、BRCA1、BRCA2、CHEK2和PALB2的PV与乳腺癌风险强相关。
  • PALB2 PV且有家族史者50岁累积风险为35.5%,无PV无家族史者仅2.4%。
  • PV特异性累积风险因种族和可改变风险因素而异。

核心结论

  • 基于人群的乳腺癌累积风险估计因家族史和可改变风险因素而异。
  • 这些估计有助于识别最受益于强化筛查和预防策略的个体。

研究设计与样本

  • 采用CARRIERS联盟13项美国乳腺癌病例对照研究的汇总数据。
  • 使用iCARE模型结合PV状态与发病和死亡统计估计累积风险。

主要发现

  • ATM、BRCA1、BRCA2、CHEK2和PALB2的PV与乳腺癌风险强相关,BRCA1和PALB2 PV存在家族史异质性证据。
  • 50岁累积风险从无PV无家族史的2.4%(95%CI 2.4-2.4)至PALB2 PV携带者有家族史的35.5%(95%CI 21.6-55.1)。
  • 50岁未诊断乳腺癌者80岁累积风险从非携带者无家族史的11.1%(95%CI 11.0-11.2)至PALB2携带者有家族史的70.5%(95%CI 52.8-83.5)。
  • PV特异性累积风险估计在种族和可改变流行病学风险因素定义的亚组间存在差异。

临床怎么用

  • 可利用PV状态、家族史和可改变风险因素进行个体化乳腺癌风险分层。
  • 识别高风险个体以优化强化筛查和预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Inherited pathogenic variants (PVs) in known predisposition genes can greatly increase breast cancer risk, but the combined impact of PV status, family history, and other factors on breast cancer risk in the general US population has not been well described. OBJECTIVE: To evaluate population-based breast cancer risk estimates for those with established PVs overall and stratified by first-degree family history of breast cancer and other factors. DESIGN, SETTING, AND PARTICIPANTS: This study used pooled data from 13 US-based breast cancer case-control studies participating in the Cancer Risk Estimates Related to Susceptibility (CARRIERS) consortium. Enrollment for individual studies occurred between 1976 and 2013, and results are based on data released March 2023, with analyses conducted from June 2022 to July 2025. EXPOSURES: PVs, breast cancer family history, self-reported race and ethnicity, and established risk factors. MAIN OUTCOMES AND MEASURES: Breast cancer rate ratios for PVs in 7 genes were estimated from the CARRIERS consortium. PV status and incidence and mortality statistics were combined using the Individualized Coherent Absolute Risk Estimation (iCARE) model to estimate conditional cumulative breast cancer risks and 95% CIs, stratified by family history and standardized to the US population. Models that incorporated population-based data and published estimates for established epidemiologic risk factors were also evaluated. RESULTS: A total of 67 692 women were studied, including 33 841 who were diagnosed with breast cancer. PVs in ATM, BRCA1, BRCA2, CHEK2, and PALB2 were strongly associated with breast cancer risk, with BRCA1 and PALB2 PVs showing evidence of heterogeneity by family history. In models considering PVs, family history, and established risk factors, the estimated cumulative risks of breast cancer by age 50 years ranged from 2.4% (95% CI, 2.4-2.4) in women with no PVs and no family history to 35.5% (95% CI, 21.6-55.1) in PALB2 PV carriers with a family history. Among women who have not been diagnosed with breast cancer by age 50 years, the cumulative risk of breast cancer by age 80 years ranged from 11.1% (95% CI, 11.0-11.2) in noncarriers with no family history to 70.5% (95% CI, 52.8-83.5) for PALB2 carriers with a family history. PV-specific cumulative risk estimates varied across subgroups defined by race and ethnicity and potentially modifiable epidemiologic risk factors. CONCLUSIONS AND RELEVANCE: In this study, population-based estimates of cumulative breast cancer risk for established PVs, as informed by the CARRIERS case-control sample, varied by family history and potentially modifiable risk factors. These estimates provide guidance for identifying individuals who will most benefit from enhanced screening and prevention strategies.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. O'Brien KM, Keil AP, Taylor JA, et al. Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women. JAMA Oncol. 2025. PMID: 41066089. doi:10.1001/jamaoncol.2025.3875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。